Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

To compare the effects of dydrogesterone and calcium plus vitamin D in women with severe premenstrual syndrome (PMS).

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, women only.

The collected data were then analyzed by repeated-measurement design and multilevel modeling tests.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Calcium, Dydrogesterone, Premenstrual Syndrome, Progestins and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.